Exploratory clinical research of tacrolimus 0.1% solution for the bleb maintaining effects after trabeculectomy

Exploratory clinical research of tacrolimus 0.1% solution for the bleb maintaining effects after trabeculectomy - Bleb maintaining effects of tacrolimus 0.1% solution after trabeculectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016976

Enrollment

Registered

2015-05-01

Start date

2015-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary open angle glaucoma, Normal tension glaucoma, Pseudo-exfoliation glaucoma

Interventions

Target drug: tacrolimus 0.1% solution control: artificial tear (My Tear eye drop)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a) Patients with POAG, or NTG, or PE glaucoma b) Patients who was performed trabeculectomy to control the IOP

Exclusion criteria

Exclusion criteria: a) patients with the active ophthalmic disease except glaucoma b) patients with retinal disease which may progress during the study period c) patients with allergic history against tacrolimus d) patients with the history of cataract surgery within one year e) patients with the history of corneal refractive surgery f) patients with the conjunctival scarring at the lesion of filtering bleb g) patients with the post-ope IOP less than 5 mmHg h) patients who was considered unsuitable by doctor in charge

Design outcomes

Primary

Measure	Time frame
Intraocular pressure difference between each group	—

Countries

Japan

Contacts

Public ContactKazuhiko Mori

Kyoto Prefectural University of Medicine Department of Ophthalmology

kmori@koto.kpu-m.ac.jp075-251-5575

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026